Senate Finance Committee leaders yesterday released the statutory text for the Prescription Drug Pricing Reduction Act of 2019 (S-2543), which closely mirrors the chairman’s mark that passed the committee in July.
Among other provisions, the bill would:

  • Make a number of changes to the Medicare Part D program, including reducing beneficiary cost-sharing and tying drug price increases to the rate of inflation.
  •  Make more information on pharmacy benefit manager practices and manufacturer drug pricing publicly available.
  •  Change how Medicare calculates Part B prescription drug payment amounts to lower spending and beneficiary out-of-pocket costs; apply "site-neutral" payment cuts to drug administration services furnished in grandfathered off-campus provider-based departments; and cap at $1,000 the add-on payment for each Part B drug paid under the average sales price or wholesale acquisition cost methodology. 
  •  Allow Medicaid to pay for gene therapies for rare disease through new risk-sharing value-based agreements; pressure manufacturers to lower list prices and report more accurate calculations of their rebate obligations; and prevent spread pricing by PBMs in the Medicaid program. 
  •  Increase the Medicaid rebate cap from 100% to 125% of a drug's average manufacturing price, intended to discourage drug manufacturers' price increases in non-Medicaid markets; and allow states to apply Medicaid drug rebate requirements to drugs provided in outpatient hospital services through bundled or value-based payment arrangements. 

Related News Articles

A federal judge today reaffirmed her previous order to the Centers for Medicare…
The House Energy and Commerce Committee last night approved a revised version of the Lower Prescription Drug Costs Now Act.
Two House committees today marked up revised versions of the Lower Prescription Drug Costs Now Act (H.R. 3) — legislation that would make a series of changes…
The average launch prices for new brand-name drugs and new generic drugs have skyrocketed since 2006, according to an analysis from 46brooklyn.
The Centers for Medicare & Medicaid Services today published its star ratings for 2020 Medicare Advantage and prescription drug plans.
The California Office of Statewide Health Planning and Development recently released the nation’s first mandatory data on wholesale acquisition cost increases…